{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '12. Any of the following conditions (including but not limited to the following) that are judged by the', \"Investigator to be clinically significant and/or to affect the subject's ability to participate in this study:\", 'impaired hepatic function.', 'any systemic infection.', 'hematological, hepatic, renal, endocrine disorder (except for hypothyroidism).', 'gastrointestinal disease.', 'malignancy (excluding basal cell carcinoma).', 'current neuropsychological condition with or without drug therapy.', '-', 'Subjects with history or current diagnosis of active Attention Deficit Hyperactivity Disorder', '(ADHD) can be included in the study if symptoms of ADHD are considered stable by the treating', 'physician and such history is documented by the Investigator.', '-', 'Subjects with history or current diagnosis of ADHD on medications are eligible for inclusion if they', 'are on stable active drug therapy and have stable symptoms for at least 30 days before the screening', 'visit as documented in the medical history by the Investigator. Subjects may not be withdrawn from', 'ADHD treatment medications during screening and/or throughout the study. If ADHD treatment', 'medications are planned to be withdrawn or withdrawn by the treating physician during the study,', 'then the subject should be considered ineligible or early terminated, respectively.', 'cardiovascular disease (eg, uncontrolled hypertension).', 'respiratory disease other than mild asthma (per Investigator clinical judgement).', '13. Any major surgery (as assessed by the Investigator) within 4 weeks before the Screening Visit (Visit 1).', '14. A requirement for the chronic use of tricyclic anti-depressants.', '15. Dependence (in the opinion of the Investigator) on nasal, oral, or ocular decongestants, nasal topical', 'antihistamines, or nasal steroids.', '16. Active pulmonary disorder or infection (including but not limited to bronchitis, pneumonia, or influenza),', 'upper respiratory tract or sinus infection within the 14 days prior to the Screening Visit (Visit 1) or the', 'development of respiratory infections during the placebo run-in period. Subjects with mild asthma (as', 'judged by the Investigator) are allowable on the condition that treatment is limited to inhaled short-acting', 'beta-agonists only (up to 8 puffs per day).', '17. Use of antibiotic therapy for acute conditions within 14 days prior to Screening Visit (Visit 1). Low doses', 'of antibiotics taken for prophylaxis are allowed if the therapy was started prior to the Screening Visit', '(Visit 1) and is expected to continue at the same stable dose throughout the clinical study duration.', '18.', 'Posterior subcapsular cataracts or glaucoma, or any other ocular disturbances or other listed related', 'conditions (as applicable) including:', 'history of increased intraocular pressure.', 'history of retinal detachment surgery.', 'history of incisional eye surgery (other than unilateral cataract extraction or laser-assisted in situ', 'keratomileusis).', 'history of penetrating ocular trauma, severe blunt ocular trauma.', 'evidence of uveitis, iritis, or other inflammatory eye disease during screening.', 'presence of ocular herpes simplex.', '19. Known history of hypothalamic-pituitary-adrenal axis impairment.', '20. Existence of any significant surgical or medical condition, or clinically significant physical finding (eg,', 'significant nasal polyps or other clinically significant respiratory tract malformations/nasal structural', 'abnormalities, significant nasal trauma [such as nasal piercing] or significant nasal septal deviation) which,', \"in the opinion of the Investigator (or in consultation with the Sponsor's medical monitor/designee),\", 'Glenmark', 'CONFIDENTIAL', 'Page 7 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'significantly interferes with the absorption, distribution. metabolism or excretion of the study medication', \"or significantly interferes with nasal air flow or interferes with the subject's ability to reliably complete the\", 'AR Assessment Diary.', '21. Participation in any investigational non-biological drug clinical study in the 30 days or investigational', 'biological drug in the 120 days preceding the Screening Visit (Visit 1) or planned participation in another', 'investigational clinical study at any time during the current study.', '22. Initiation of immunotherapy injections or immunosuppressive/immune-modulator medications within', '60 days preceding the Screening Visit (Visit 1) and/or currently undergoing treatment with immunotherapy', 'or immunosuppressive/immune-modulator medications. Topical pimecrolimus cream or tacrolimus', 'ointment treatment, if initiated at least 30 days prior to screening and maintained on stable dose, is', 'acceptable. A 180-day washout period is required following the last dose of sublingual immunotherapy', '(investigational or other) prior to the Screening Visit (Visit 1).', '23. Use of topical corticosteroids in concentrations in excess of 1% hydrocortisone, or equivalent, within', '30 days prior to the Screening Visit (Visit 1); use of a topical hydrocortisone or equivalent in any', 'concentration covering greater than 20% of the body surface or the presence of an underlying condition (as', 'judged by the Investigator) that can reasonably be expected to require treatment with such preparations', 'over the clinical study duration.', '24. Previous participation in another GSP 301 NS study as a randomized subject.', '25. Clinical study participation by clinical investigator site employees and/or their immediate relatives.', '26. Study participation by more than 1 subject from the same household at the same time. However, after the', 'completion/discontinuation by 1 subject in the household, another subject from the same household may be', 'screened.', '27. Known to have failed to show symptom improvement with any approved/marketed monotherapy', 'component of the GSP 301 NS (ie, NASONEX NS, PATANASE NS, or both) as judged by the', 'Investigator.', 'Randomization Criteria (at the Randomization Visit (RV) - Visit 2):', '1. Continued general good health and continued eligibility according to the inclusion and exclusion criteria.', '2.', 'Has not left the known pollen area for the investigative site for 24 hours or longer during the last 7 days of', 'the placebo run-in period.', '3.', 'No adverse event (AE) that has altered eligibility according to the inclusion and exclusion criteria.', '4. Minimum 12-hour subject-reported rTNSS of an average of 6, (out of a possible 12) during the last 4 days', 'of the placebo run-in period (average of last 8 consecutive AM and PM assessments from the Day -4 PM', 'assessment to the AM assessment on the day of randomization).', '5.', 'A 12-hour subject-reported reflective nasal congestion score of an average of 2 or greater during the last', '4 days of the placebo run-in period (average of last 8 consecutive AM and PM assessments from Day -4', 'PM assessment to the AM assessment on the day of randomization).', '6.', 'Adequate symptom assessment diary compliance (with assistance from parent/guardian/caregiver, as', 'needed) - inadequate compliance is defined as missing one or more of the entries on 2 or more assessment', 'sessions (AM or PM) during the last 4 days of the placebo run-in period (during the last 8 consecutive AM', 'and PM assessments from Day -4 PM assessment to the AM assessment on the day of randomization).', '7.', 'Adequate study medication compliance - each subject must have taken his/her single-blind placebo', 'medication (with assistance from parent/guardian/caregiver, as needed) for at least 80% of the entire', 'placebo run-in period as reported in the symptom assessment diary.', '8.', 'Absence of common cold, upper respiratory infections, otitis, lower respiratory infections or acute sinusitis', 'for 14 days prior to the Randomization Visit (Visit 2).', '9.', 'No use of prohibited concomitant medications during the placebo run-in period.', 'Glenmark', 'CONFIDENTIAL', 'Page 8 of 90']\n\n###\n\n", "completion": "END"}